In six healthy volunteers, the new psychoactive substance MDAI at 3.0 mg/kg produced subjective effects comparable to 125 mg of MDMA, including increased blood pressure, but did not raise heart rate or body temperature. MDAI increased cortisol and prolactin levels, appeared in serum about 20 minutes after ingestion, and remained detectable for at least 4 days in serum and 6 days in urine. The drug was well tolerated. Further research is needed to evaluate whether MDAI might have medicinal applications.
A 5-day meditation training focusing on body and breath awareness did not increase pain tolerance more than no intervention in healthy adults. Pain tolerance actually increased in both the meditation and control groups, with a larger increase in the control group. Naloxone infusion showed a trend toward decreasing pain tolerance in both groups. The meditation group made fewer errors on an attention test. Blood samples detected morphine and morphine metabolites sporadically with no clear pattern. The intended link between meditation, attention, mindfulness, and pain tolerance was not supported under conditions designed to avoid placebo effects.